Quintet Private Bank Europe S.A. Purchases 215 Shares of Zoetis Inc. (NYSE:ZTS)

Quintet Private Bank Europe S.A. grew its position in Zoetis Inc. (NYSE:ZTS) by 0.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,674 shares of the company’s stock after purchasing an additional 215 shares during the quarter. Quintet Private Bank Europe S.A.’s holdings in Zoetis were worth $6,251,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of ZTS. American International Group Inc. raised its stake in Zoetis by 1.2% during the 4th quarter. American International Group Inc. now owns 143,714 shares of the company’s stock valued at $28,365,000 after purchasing an additional 1,717 shares during the period. EP Wealth Advisors LLC lifted its holdings in shares of Zoetis by 3.0% in the fourth quarter. EP Wealth Advisors LLC now owns 204,870 shares of the company’s stock worth $40,435,000 after buying an additional 5,990 shares in the last quarter. Syon Capital LLC boosted its position in shares of Zoetis by 19.1% during the fourth quarter. Syon Capital LLC now owns 5,156 shares of the company’s stock worth $1,018,000 after acquiring an additional 828 shares during the last quarter. Neo Ivy Capital Management bought a new position in shares of Zoetis during the fourth quarter worth $40,000. Finally, Scarborough Advisors LLC purchased a new position in Zoetis during the fourth quarter valued at $89,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the transaction, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at $2,725,267.59. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. HSBC dropped their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. The Goldman Sachs Group reduced their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research note on Monday, May 6th. Stifel Nicolaus lowered their target price on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. Barclays decreased their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Finally, Piper Sandler restated an “overweight” rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $211.75.

Zoetis Trading Down 0.4 %

Shares of NYSE ZTS traded down $0.77 during mid-day trading on Friday, reaching $170.55. The company had a trading volume of 2,225,314 shares, compared to its average volume of 2,110,836. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The business’s 50-day moving average is $165.75 and its 200-day moving average is $179.51. The stock has a market cap of $77.82 billion, a price-to-earnings ratio of 32.86, a price-to-earnings-growth ratio of 2.65 and a beta of 0.88. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The business had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same period last year, the company posted $1.31 earnings per share. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. Equities analysts expect that Zoetis Inc. will post 5.76 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 1.01%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s payout ratio is 33.33%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.